Trials with INBRX-109
Every colorectal cancer trial that includes this drug. Those looking for patients come first.
Showing 1–1 of 1
NCT03715933
This is a first-in-human, open-label, non-randomized, three-part phase 1 trial of INBRX-109, which is a recombinant humanized tetravalent antibody targeting the human death receptor 5 (DR5).